Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at eGFR ≥20 and combining with a nonsteroidal MRA. Diabzen, [S. l.], v. 4, n. 17, p. 34–35, 2026. Disponível em: https://thediabzen.com/index.php/d/article/view/60. Acesso em: 28 jul. 2026.